SCHEMBL89093

SCHEMBL89093

Cc1ccc2c(c1)N(CCOC(C)C)C(=O)C(C)(C)O2

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
POLB P06746 4/20 0.47
KMT2A Q03164 3/20 0.47
MEN1 O00255 2/20 0.47
CYP2C19 P33261 2/20 0.45
CYP3A4 P08684 1/20 0.45
USP2 O75604 2/20 0.44
ALDH1A1 P00352 3/20 0.43
MAPT P10636 2/20 0.43
RECQL P46063 1/20 0.43
SMN1; SMN2 Q16637 2/20 0.42
HPGD P15428 1/20 0.42
TSHR P16473 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
REN P00797 3/20 0.42
ALOX15 P16050 1/20 0.40
CYP1A2 P05177 1/20 0.38
CYP2C9 P11712 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL89102 0.86 REN (0.51) POLBKMT2AMEN1CYP2C19USP2
SCHEMBL89408 0.84 ALDH1A1 (0.48) POLBKMT2AMEN1CYP2C19CYP3A4
SCHEMBL89392 0.83 MAPT (0.45) POLBKMT2AMEN1CYP2C19USP2
SCHEMBL13091047 0.82 ALDH1A1 (0.47) POLBKMT2AMEN1CYP2C19USP2
SCHEMBL89417 0.81 REN (0.59) POLBKMT2AMEN1CYP2C19CYP3A4
SCHEMBL13434192 0.81 ALDH1A1 (0.43) POLBKMT2AMEN1USP2ALDH1A1
SCHEMBL89090 0.81 MAPT (0.48) POLBKMT2AMEN1CYP2C19USP2
SCHEMBL13434190 0.81 REN (0.56) POLBKMT2AMEN1CYP2C19CYP3A4
SCHEMBL90354 0.80 ALDH1A1 (0.50) POLBKMT2AMEN1CYP2C19CYP3A4
SCHEMBL89403 0.79 REN (0.46) POLBKMT2AMEN1USP2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2420491-B1 3 , 5-SUBSTITUED PIPERIDINE COMPOUNDS AS RENIN INHIBITORS NOVARTIS AG (CH) 2013-07-03 EP disclosed
US-8129411-B2 Organic compounds NOVARTIS AG (CH) 2012-03-06 US disclosed
EP-2420491-A1 3 , 5-substitued piperidine compounds as renin inhibitors Novartis AG (CH) 2012-02-22 EP disclosed
US-20090192148-A1 Organic Compounds NOVARTIS AG (CH) 2009-07-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090192148-A1 Organic Compounds REN, ACE, AGTR1 POLB 589/4885KMT2A 3129/4885MEN1 2336/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.